Shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) saw an uptick in trading volume on Wednesday . 308,297 shares changed hands during mid-day trading, a decline of 13% from the previous session’s volume of 355,262 shares.The stock last traded at $10.35 and had previously closed at $10.50.

The stock has a 50-day moving average price of $13.39 and a 200 day moving average price of $11.22. The stock has a market cap of $513.56 million and a P/E ratio of 19.06.

SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter. The business had revenue of $36.50 million for the quarter, compared to the consensus estimate of $33.60 million. On average, equities analysts predict that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current year.

Other hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP boosted its stake in SciClone Pharmaceuticals by 20.0% in the fourth quarter. GSA Capital Partners LLP now owns 325,115 shares of the specialty pharmaceutical company’s stock worth $2,991,000 after buying an additional 54,227 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its stake in SciClone Pharmaceuticals by 32.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 198,570 shares of the specialty pharmaceutical company’s stock worth $1,827,000 after buying an additional 48,470 shares during the period. Matarin Capital Management LLC purchased a new stake in SciClone Pharmaceuticals during the fourth quarter worth approximately $1,600,000. Finally, Dimensional Fund Advisors LP boosted its stake in SciClone Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,559,182 shares of the specialty pharmaceutical company’s stock worth $23,544,000 after buying an additional 53,987 shares during the period.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.